论文部分内容阅读
真性红细胞增多症(简称真红)是一种骨髓增殖性疾患,进展缓慢但不能自愈。应用α2a干扰素(IFN)治疗这种疾病是一种新的方法。作者采用Fourier-transform红外显微分光镜检测IFN治疗真红病人的表现及其治疗反应。 11例病人,7例男性,4例女性,均符合美国真红研究组的诊断标准。应用重组IFN-α2a治疗,开始剂量为150万单位皮下注射,3次/周,共两周。以后改为300万单位,3次/周,共10周,维持剂量为300
Polycythemia vera (referred to as true red) is a myeloproliferative disorder, slow progress but can not be self-healing. The application of α2a interferon (IFN) to treat this disease is a new approach. The authors used Fourier-transform infrared microscopy to detect IFN in patients with true red performance and treatment response. Eleven patients, seven males and four females, all met the diagnostic criteria of the U.S. True Red Study Group. Application of recombinant IFN-α2a treatment, the initial dose of 1.5 million units subcutaneously, 3 times / week for a total of two weeks. After the change to 3 million units, 3 times / week for a total of 10 weeks to maintain the dose of 300